Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein

Virology Journal

Volumn 9, Issue , 2012, Pages

  Luo, Jian ^b   Zheng, Dan ^b   Zhang, Wenjie ^d   Fang, Fang ^a   Wang, Hanzhong ^c   Sun, Ying ^b   Ding, Yahong ^b   Xu, Chengfei ^b   Chen, Quanjiao ^c   Zhang, Hongbo ^c   Huang, Ding ^e   Sun, Bing ^f   Chen, Ze ^a,b,c  

^a HUNAN NORMAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

DNA prime; Influenza; Intranasal protein boost; Recombinant NP

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; NUCLEOPROTEIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DNA PRIME INTERNASAL PROTEIN BOOST; ELECTROPORATION; GENE EXPRESSION; IMMUNE RESPONSE; IN VIVO STUDY; INFLUENZA A; INFLUENZA VIRUS A H9N2; MOUSE; NONHUMAN; PLASMID; SURVIVAL RATE; T LYMPHOCYTE; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; MICE; NUCLEOCAPSID; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY MUCOSA; VACCINES, DNA;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 84869871946     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-286     Document Type: Article

References (49)

1. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti influenza. Yewdell JW, Bennink JR, Smith GL, Moss B, Proc Natl Acad Sci USA 1985 82 1785 1789 10.1073/pnas.82.6.1785 3872457 (Pubitemid 15085262)
2. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Townsend AR, Gotch FM, Davey J, Cell 1985 42 457 467 10.1016/0092-8674(85)90103- 5 2411422
3. Cell-mediated protection in influenza infection. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC, Emerg Infect Dis 2006 12 48 54 10.3201/eid1201.051237 16494717 (Pubitemid 43143535)
4. Purified influenza virus nucleoprotein protects mice from lethal infection. Wraith DC, Vessey AE, Askonas BA, J Gen Virol 1987 68 433 440 10.1099/0022-1317-68-2-433 3493324 (Pubitemid 17007830)
5. Protection against multiple influenza A subtypes by intranasal administration of recombinant nucleoprotein. Guo L, Zheng M, Ding Y, Li D, Yang Z, Wang H, Chen Q, Sui Z, Fang F, Chen Z, Arch Virol 2010 155 1765 1775 10.1007/s00705-010-0756-3 20652335
6. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, Kobasa D, Wilson JM, Vaccine 2007 25 6845 6851 10.1016/j.vaccine.2007.07.035 17728024 (Pubitemid 47398928)
7. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. Ashraf S, Kong W, Wang S, Yang J, Curtiss R 3rd, Vaccine 2011 29 3990 4002 10.1016/j.vaccine.2011.03.066 21466806
8. Heterologous protection against influenza by injection of DNA encoding a viral protein. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Science 1993 259 1745 1749 10.1126/science.8456302 8456302 (Pubitemid 23114660)
9. Pandemic preparedness: toward a universal influenza vaccine. Roose K, Fiers W, Saelens X, Drug News Perspect 2009 22 80 92 10.1358/dnp.2009.22.2. 1334451 19330167
10. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ, Vaccine 2005 23 5404 5410 10.1016/j.vaccine.2005.04.047 16011865 (Pubitemid 41579312)
11. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Chen Z, Sahashi Y, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S, Vaccine 1998 16 1544 1549 10.1016/S0264-410X(98)00043-7 9711802 (Pubitemid 28366091)
12. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Chen Q, Kuang H, Wang H, Fang F, Yang ZD, Zhang Z, Zhang X, Chen Z, Virus Genes 2009 38 30 38 10.1007/s11262-008-0305-2 19067149
13. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, Andersen H, Tumpey TM, Nabel GJ, PLoS One 2010 5 9812 10.1371/journal.pone.0009812 20352112
14. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Nguyen HH, Moldoveanu Z, Novak MJ, van Ginkel FW, Ban E, Kiyono H, McGhee JR, Mestecky J, Virology 1999 254 50 60 10.1006/viro.1998.9521 9927573 (Pubitemid 29391713)
15. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL, Vaccine 2009 27 6512 6521 10.1016/j.vaccine.2009.08.053 19729082
16. Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL, PLoS One 2010 5 13162 10.1371/journal.pone. 0013162 20976273
17. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. Furuya Y, Chan J, Regner M, Lobigs M, Koskinen A, Kok T, Manavis J, Li P, Müllbacher A, Alsharifi M, J Virol 2010 84 4212 4221 10.1128/JVI.02508-09 20164231
18. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Sui Z, Chen Q, Fang F, Zheng M, Chen Z, Vaccine 2010 28 7690 7698 10.1016/j.vaccine.2010.09.019 20870054
19. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z, Arch Virol 2010 155 535 544 10.1007/s00705-010-0621-4 20195654
20. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F, Umeda K, Tamura Y, Okuda K, Klinman D, Xin K, Okuda K, Virology 2006 354 48 57 10.1016/j.virol.2006.04.015 16945400 (Pubitemid 44441505)
21. The prime-boost strategy: exciting prospects for improved vaccination. Ramshaw IA, Ramsay AJ, Immunol Today 2000 21 163 165 10.1016/S0167-5699(00) 01612-1 10740236 (Pubitemid 30184783)
22. Homologous prime-boost vaccination. Lu S, Curr Opin Immunol 2009 21 346 351 10.1016/j.coi.2009.05.016 19500964
23. Evaluation of the T cells and costimulatory molecules in the protective efficacy of 30 kDa secretory protein against experimental tuberculosis. Yadav D, Khuller G, Immunol Cell Biol 2001 79 207 212 10.1046/j.1440-1711.2001.00998.x 11380672 (Pubitemid 32522167)
24. DNA prime followed by protein boost enhances neutralization and Th1 type immunity against FMDV. Jin H, Kang Y, Xiao C, Zhu K, Ma Y, Xie Q, Ma J, Xie Q, He C, Yang Z, Sun Z, Zhang X, Chen M, Zhang F, Wang B, Viral Immunol 2005 18 539 548 10.1089/vim.2005.18.539 16212533
25. A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in nave and infection-primed mice. Ruitenberg KM, Walker C, Love DN, Wellington JE, Whalley JM, Vaccine 2000 18 1367 1373 10.1016/S0264-410X(99)00400-4 10618534 (Pubitemid 30017849)
26. A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection. Yang K, Whalen BJ, Tirabassi RS, Selin LK, Levchenko TS, Torchilin VP, Kislauskis EH, Guberski DL, J Immunol 2008 180 6159 6167 18424737
27. Mechanism of protective immunity against influenza virus infection in mice without antibodies. Epstein SL, Lo CY, Misplon JA, Bennink JR, J Immunol 1998 160 322 327 9551987 (Pubitemid 28116745)
28. Rectification of ageassociated deficiency in cytotoxic T cell response to influenza a virus by immunization with immune complexes. Zheng B, Zhang Y, He H, Marinova E, Switzer K, Wansley D, Mbawuike I, Han S, J Immunol 2007 179 6153 6159 17947690
29. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, J Immunol 2008 181 4168 4176 18768874
30. Regulation of anti-nucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, Randall TD, Lund FE, Kaminski DA, J Virol 2011 85 5027 5035 10.1128/JVI.00150-11 21367900
31. Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD, Kaminski DA, J Immunol 2011 186 4331 4339 10.4049/jimmunol.1003057 21357542
32. Review Heterosubtypic immunity to influenza A virus: where do we stand? Grebe KM, Microbes Infect 2008 10 1024 1029 10.1016/j.micinf.2008.07.002 18662798
33. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection:homing properties rather than initial frequencies are crucial. Cerwenka A, Morgan TM, Dutton RW, J Immunol 1999 163 5535 5543 10553081
34. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. Topham DJ, Tripp RA, Doherty PC, J Immunol 1997 159 5197 5200 9548456 (Pubitemid 127470043)
35. CD8 T cells utilize TRAIL to control influenza virus infection. Brincks EL, Katewa A, Kucaba TA, J Immunol 2008 181 4918 4925 18802095
36. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. Brown DM, Dilzer AM, Meents DL, Swain SL, J Immunol 2006 177 2888 2898 16920924 (Pubitemid 44277804)
37. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL, J Virol 2010 84 9217 9226 10.1128/JVI.01069-10 20592069
38. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. Mukhtar MM, Li S, Li W, Wan T, Mu Y, Wei W, Kang L, Rasool ST, Xiao Y, Zhu Y, Wu J, Int J Biochem Cell Biol 2009 41 554 560 10.1016/j.biocel.2008.07.001 18687409
39. Intracellular neutralization of virus by immunoglobulin A antibodies. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG, Proc Natl Acad Sci U S A 1992 89 6901 6905 10.1073/pnas.89.15.6901 1323121
40. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. Mazanec MB, Coudret CL, Fletcher DR, J Virol 1995 69 1339 1343 7815518
41. Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. Fujioka H, Emancipator SN, Aikawa M, Huang DS, Blatnik F, Karban T, DeFife K, Mazanec MB, J Exp Med 1998 188 1223 1229 10.1084/jem.188.7.1223 9763601 (Pubitemid 28478010)
42. Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections. Zhong W, Liu F, Dong L, Lu X, Hancock K, Reinherz EL, Katz JM, Sambhara S, PLoS One 2010 5 10583 10.1371/journal.pone.0010583 20485501
43. Location of antigenic sites recognized by monoclonal antibodies in the influenza A virus nucleoprotein molecule. Varich NL, Kochergin-Nikitsky KS, Usachev EV, Usacheva OV, Prilipov AG, Webster RG, Kaverin NV, J Gen Virol 2009 90 1730 1733 10.1099/vir.0.010660-0 19297605
44. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin or neuraminidase-expressing DNA in BALB/c mice. Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, Wang H, Zhang R, Chen Z, Biochem Biophys Res Commun 2006 343 1124 1131 10.1016/j.bbrc.2006.03.088 16580631
45. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Chen J, Fang F, Li X, Chang H, Chen Z, Vaccine 2005 23 4322 4328 10.1016/j.vaccine.2005. 03.035 15925433 (Pubitemid 40991237)
46. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Vaccine 2000 18 3214 3222 10.1016/S0264-410X(00)00149-3 10869766 (Pubitemid 30408197)
47. Identification and characterization of T helper epitopes in the nucleoprotein of influenza A virus. Gao XM, Liew FY, Tite JP, J Immunol 1989 143 3007 3014 2478631 (Pubitemid 19281852)
48. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. Deng Y, Yewdell JW, Eisenlohr LC, Bennink JR, J Immunol 1997 158 1507 1515 9029084 (Pubitemid 127469502)
49. Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. Larke N, Murphy A, Wirblich C, Teoh D, Estcourt MJ, McMichael AJ, Roy P, Hanke T, J Virol 2005 79 14822 14833 10.1128/JVI.79.23.14822-14833. 2005 16282482 (Pubitemid 41636280)